Brought to you by 
AZ to buy Wellstat's pediatric priority review voucher upon FDA approval of uridine
21 Sep 2020
Executive Summary
Wellstat Therapeutics Corp. (oncology, metabolic, neurodegenerative, and neurometabolic disease treatments) agreed to sell to AstraZeneca PLC a rare pediatric disease priority review voucher (PRV) that Wellstat expects to receive when its uridine triacetate is approved to treat hereditary orotic aciduria (HOA). Financial terms were not disclosed.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Priority Review Voucher (PRV) Sale
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AZ to buy Wellstat's pediatric priority review voucher upon FDA approval of uridine
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice